Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma
Karapetyan, L.; Cillo, A. R.; Wang, S.; Karunamurthy, A.; Massa, R. C.; Rohatgi, A.; Deitrick, C.; Najjar, Y. G.; Davar, D.; Luke, J. J.; Sander, C.; Kunning, S. R.; Rose, A.; Bradley, S.; Rush, E.; Joy, M.; Bao, R.; Wang, H.; Vignali, D. A. A.; Bruno, T. C.; Kirkwood, J. M.
Show abstract
Simultaneous blockade of lymphocyte activation gene-3 (LAG-3) and programmed-death-1 (PD-1) pathways enhance anti-tumor activity in patients with melanoma. It is not known if this immunotherapy induces unique immune modulation or how this may relate to clinical outcomes, compared to the single modalities. We conducted a randomized three-arm phase 2 trial (NCT03743766) in advanced melanoma comparing lead-in treatment with one cycle of relatlimab-(n=14), nivolumab-(n=15), and nivolumab-relatlimab (n=14) as first-line therapy, followed by combination nivolumab-relatlimab, to assess the impact of the lead-in therapy on immune populations, related to objective response rate, progression-free survival (PFS) and major pathologic response on biopsy (MPRbx). Unexpectedly, diminished efficacy was observed when nivolumab or relatlimab was given as a lead-in monotherapy, despite receipt of the combination subsequent to week 4. MPRbx at week 4 was significantly higher with nivolumab- and combination vs. relatlimab-lead-in, mechanistically correlated with higher IFN-g and TCR signaling in CD8+ T cells, and was associated with superior PFS. Relatlimab lead-in was characterized by clustering of CD8+ T and FOXP3+ T regulatory cells in the tumor microenvironment, enrichment in inhibitory receptor pathways and associated with worse PFS. Combination therapy increased the fraction of CD8+TEM cells in association with response to therapy while patients with progressive disease demonstrated decrease in CD14+CD16-HLA-DRlowCD33dim monocytic populations. The analyses of component agents afforded by this novel lead-in trial has identified differential clinical and immunological modulation of anti-PD1 and anti-LAG3 in comparison to the combination therapy. HighlightsO_LILead-in monotherapy with nivolumab or relatlimab reduces efficacy to the combo C_LIO_LIMPRbx serves as an early surrogate marker of response and long-term PFS C_LIO_LIRelatlimab lead-in led to CD8+ T cell:Treg clustering in the TME and poor PFS C_LIO_LICombo therapy non-responders had decreased CD14+CD16-HLA-DRlowCD33dim monocytes C_LI
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 96%
- Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma 96%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 95%
Similar papers in this journal
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 95%
- A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer 94%
- Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors 94%
Similar papers in this journal
- Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses 95%
- Increased Tryptophan, But Not Increased Glucose Metabolism, Predict Resistance of Pembrolizumab in Stage III/IV Melanoma 94%
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 94%
Similar papers in this journal
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 98%
- Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy 95%
- Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer. 94%
Similar papers in this journal
- IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models 94%
- Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments 93%
- Tumor-educated Gr1+CD11b+ cells instigate breast cancer metastasis by twisting cancer cells plasticity via OSM/IL6-JAK signaling 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.